LTZ Therapeutics Names Phillip Lee as Chief Financial Officer

REDWOOD CITY, California – August 17, 2026 – LTZ Therapeutics, a clinical-stage, immunotherapy-focused biotechnology company, today announced the appointment of Phillip Lee as Chief Financial Officer (CFO), effective immediately.

"We are excited to welcome Phillip at this pivotal stage of our growth," said Robert Li, Ph.D., Founder and Chief Executive Officer of LTZ Therapeutics. "As an experienced CFO and former investment banker, his deep biotech finance and transaction expertise directly supports our mission to pioneer novel therapies for oncology and autoimmune diseases. His leadership will sharpen our strategic execution in capital allocation and business development, accelerating the translation of innovative science into impactful global therapies for patients and shareholders alike."

"I am thrilled to join LTZ at such a dynamic time. The team’s relentless focus on pioneering a novel modality is truly inspiring," Mr. Lee said. "With two programs already in the clinic and a robust early-stage pipeline, LTZ is well positioned to turn complex science into life-saving treatments. I look forward to collaborating with my LTZ colleagues to execute and generate long-term value."

Mr. Lee brings nearly two decades of strategic finance and advisory experience in the biotechnology industry, having guided companies through critical growth phases, capital raises, and complex strategic transactions. Throughout his career, he has helped raise over $1 billion in capital, including crossover rounds, IPOs, and public follow-on financings. He has also worked on more than $20 billion of M&A transactions, encompassing company acquisitions, strategic partnerships, asset acquisitions, mergers, and spin-offs.

Mr. Lee's experience includes previously serving as CFO at Vaxart, CFO & Chief Operating Officer at Clover Biopharmaceuticals, and holding senior finance leadership positions at several other biotechnology companies. Mr. Lee began his career in investment banking and was a Principal and founding member of Centerview Partners' healthcare advisory practice. Mr. Lee holds dual bachelor's degrees in Electrical Engineering & Computer Sciences and Business Administration from the University of California, Berkeley. 

LTZ's Scientific Approach

LTZ's approach focuses on the fusion of reverse translational science, with a deep understanding of tumor microenvironment (TME) biology – especially myeloid biology. Macrophages appear to be one of the most prevalent immune cell populations in TME of various hematologic and solid tumors. Therefore, effectively engaging and activating macrophages to kill cancer cells offers significant therapeutic potential for patients. LTZ is developing its own Universal Myeloid Cell Engager (U-MCE^TM) Platform to primarily enhance the phagocytic function of monocytes and macrophages of different polarization states to foster anti-tumor immunity and offer potential therapeutic benefit for other non-oncology diseases.

About LTZ

LTZ Therapeutics is a clinical-stage, immunotherapy-focused biotechnology company pursuing the development of novel therapies, with the company's U-MCE^TM Platform, to improve clinical outcomes in patients with oncology and autoimmune diseases. With headquarters in Redwood City, California and operations in Shenzhen, China, LTZ is dedicated to developing myeloid engager immunotherapies for broad disease indications. For more information, please visit https://www.ltztherapeutics.com/.